Order Article Reprints

Napoletano C, Ruscito I, Bellati F, Zizzari IG, Rahimi H, Gasparri ML, Antonilli M, Panici PB, Rughetti A, Nuti M. Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets. Journal of Clinical Medicine. 2019; 8(3):380. https://doi.org/10.3390/jcm8030380

Napoletano, Chiara, Ilary Ruscito, Filippo Bellati, Ilaria Grazia Zizzari, Hassan Rahimi, Maria Luisa Gasparri, Morena Antonilli, Pierluigi Benedetti Panici, Aurelia Rughetti, and Marianna Nuti. 2019. "Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets" Journal of Clinical Medicine 8, no. 3: 380. https://doi.org/10.3390/jcm8030380

Napoletano, C., Ruscito, I., Bellati, F., Zizzari, I. G., Rahimi, H., Gasparri, M. L., Antonilli, M., Panici, P. B., Rughetti, A., & Nuti, M. (2019). Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets. Journal of Clinical Medicine, 8(3), 380. https://doi.org/10.3390/jcm8030380